Follow us on:

Linkedin Facebook

Health

Companies engaged in biotechnology, pharmaceuticals, research services, home healthcare, hospital operations, long‑term care, and the manufacture and supply of medical equipment and supplies. The sector also includes pharmaceutical retailers and providers of health‑information services. UK‑listed companies in this sector include AstraZeneca plc, GlaxoSmithKline plc, Smith & Nephew plc, Hikma Pharmaceuticals plc, ConvaTec Group plc, Spire Healthcare plc and EMIS Group plc.

Oxford Nanopore CEO Gordon Sanghera to step down

Oxford Nanopore has announced that CEO and co-founder Gordon Sanghera will step down by the end of 2026 after more than 20 years leading the company. The Board has begun a formal search for his successor as part of its succession planning, aiming to guide the business through its next phase of growth and commercialisation...
GSK

GSK’s Gepotidacin receives US FDA Priority Review for gonorrhoea treatment

GSK has announced that the US FDA has accepted for priority review a supplemental New Drug Application for gepotidacin as an oral treatment for uncomplicated urogenital gonorrhoea in patients aged 12 and over...
Nuformix

Nuformix applies for US Orphan Drug Designation for NXP002 in IPF

Nuformix has submitted an application to the US FDA for Orphan Drug Designation for tranilast, the active ingredient in its NXP002 inhaled therapy for idiopathic pulmonary fibrosis...
EDX Medical Group plc

EDX Medical Group to complete the development of new pneumonia test

EDX Medical will partner with the Intensive Care Unit at Cambridge University Hospitals NHS Foundation Trust to support the further advancement of a highly precise test that identifies the DNA or RNA of the microbes that cause lung infection in critically ill patients...
GSK plc

GSK to receive $370m settlement and royalties from mRNA patent agreement

GSK will receive a $370 million upfront payment, plus 1% royalties on US sales of certain mRNA vaccines by BioNTech and Pfizer, following a settlement linked to CureVac’s recent agreement with BioNTech...
Aptamer Group

Aptamer Group to host technical development update webinar

Aptamer will hold a webinar on 14 August 2025 at 6:00 pm BST, led by Chief Scientific Officer Dr David Bunka, to present the latest data and progress across its technical development programmes...
Hikma Pharmaceuticals plc

Hikma Pharmaceuticals reports 6% revenue growth and confirms FY outlook

Hikma Pharmaceuticals posted a 6% rise in H1 2025 revenue to $1.66 billion, supported by strong Injectables and Branded sales. Core operating profit declined 7% due to product mix and prior-year comparators, but the company expects a stronger H2...
Smith & Nephew plc

Smith & Nephew Plc delivers strong H1 with profit up 31%

Smith+Nephew reported 5.0% underlying revenue growth and a 30.6% rise in operating profit for H1 2025. EPS rose 36.6% to 33.5¢ and free cash flow surged to $244m. The company also announced a $500m share buyback for H2, supported by strong cash generation and margin expansion...
Aptamer Group

Aptamer Group reports 41% revenue growth and new licensing deals

Aptamer Group posted unaudited revenue of £1.20 million for the year ended 30 June 2025, up 41% from the previous year. The company secured two new royalty agreements and advanced multiple licensing discussions, supported by a strengthened cash position following a £1.83 million fundraise...
GSK plc

GSK raises 2025 guidance after strong Q2 performance

GSK reported Q2 2025 turnover of £8.0bn, up 6% CER, with strong growth in Specialty Medicines (+15%) and Vaccines (+9%). Core EPS rose 15% to 46.5p...
One Health Group

One Health Group a “buy” in This is Money Midas Share Tips

Analysts at Midas Share Tips described the company as well-managed and well-positioned to benefit from ongoing NHS reliance on external capacity...
GSK

GSK and Hengrui Pharma to develop up to 12 new medicine programmes

GSK plc has entered agreements with Hengrui Pharma to develop up to 12 innovative medicines, including an exclusive worldwide licence (ex‑China) for HRS‑9821, a potential best‑in‑class PDE3/4 inhibitor for COPD, for $500 million in upfront fees and up to $12 billion in milestone payments...
Physicians Capital

When buildings become health’s best asset

Investors are discovering that medical properties offer a unique blend of resilience and growth potential in unpredictable markets...
One Health Group

One Health Group PLC closely aligned with government 10-year Health Plan

AstraZeneca

AstraZeneca to invest $50bn in the US, new Virginia manufacturing site planned

AstraZeneca will invest $50bn in the United States by 2030, including a multi‑billion dollar drug substance facility in Virginia for its weight management and metabolic portfolio...

Oxford Nanopore delivers 25% revenue growth in H1 2025

Revenue rose to £105 million, up 28% constant currency, driven by PromethION growth of 59% and strong gains in Applied markets. Adjusted EBITDA loss narrowed, cash stood at £337 million and full‑year guidance remains on track...
Aptamer Group

Aptamer Group extends Unilever collaboration for deodorant Optimers

Aptamer Group has secured additional paid work from Unilever under their existing collaboration, advancing Optimers as deodorant actives with expanded stability testing ahead of on‑person trials...
GSK plc

GSK’s Arexvy FDA review accepted for adults 18-49 at increased risk

The US FDA has accepted GSK’s application to extend Arexvy to adults aged 18-49 at increased risk of severe RSV infection, supported by positive Phase IIIb data; a decision is expected in H1 2026...
AstraZeneca

AstraZeneca’s Baxdrostat meets Phase III endpoints in Hypertension trial

AstraZeneca reports that baxdrostat at 1mg and 2mg doses significantly reduced mean seated systolic blood pressure at 12 weeks versus placebo in patients with uncontrolled or treatment-resistant hypertension, meeting all primary and secondary endpoints, with a favourable safety profile...
Aptamer Group

Aptamer Group raises £2.0 million in share placing

Aptamer has raised £2.0 million (before expenses) by placing 666,666,666 new ordinary shares at 0.3 p each, representing 25.1 per cent of its enlarged issued share capital. The proceeds will accelerate commercialisation of the Optimer® platform, support in-house manufacturing, launch new biomarker services and develop AI-driven aptamer discovery...

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

Green News

View all Sustainable sectors, Plcs and news >>  

Search

Search

Latest Interviews

BrokerTalk

Funds

View all Funds, Market Insights and news >> 

FTSE 100 News

UK Broker Ratings

November 24, 2025

Oxford Nanopore CEO Gordon Sanghera to step down

Oxford Nanopore has announced that CEO and co-founder Gordon Sanghera will step down by the end of 2026 after more than 20 years leading the company. The Board has begun a formal search for his successor as part of its succession planning, aiming to guide the business through its next phase of growth and commercialisation...
GSK

GSK’s Gepotidacin receives US FDA Priority Review for gonorrhoea treatment

GSK has announced that the US FDA has accepted for priority review a supplemental New Drug Application for gepotidacin as an oral treatment for uncomplicated urogenital gonorrhoea in patients aged 12 and over...
Nuformix

Nuformix applies for US Orphan Drug Designation for NXP002 in IPF

Nuformix has submitted an application to the US FDA for Orphan Drug Designation for tranilast, the active ingredient in its NXP002 inhaled therapy for idiopathic pulmonary fibrosis...
EDX Medical Group plc

EDX Medical Group to complete the development of new pneumonia test

EDX Medical will partner with the Intensive Care Unit at Cambridge University Hospitals NHS Foundation Trust to support the further advancement of a highly precise test that identifies the DNA or RNA of the microbes that cause lung infection in critically ill patients...
GSK plc

GSK to receive $370m settlement and royalties from mRNA patent agreement

GSK will receive a $370 million upfront payment, plus 1% royalties on US sales of certain mRNA vaccines by BioNTech and Pfizer, following a settlement linked to CureVac’s recent agreement with BioNTech...
Aptamer Group

Aptamer Group to host technical development update webinar

Aptamer will hold a webinar on 14 August 2025 at 6:00 pm BST, led by Chief Scientific Officer Dr David Bunka, to present the latest data and progress across its technical development programmes...
Hikma Pharmaceuticals plc

Hikma Pharmaceuticals reports 6% revenue growth and confirms FY outlook

Hikma Pharmaceuticals posted a 6% rise in H1 2025 revenue to $1.66 billion, supported by strong Injectables and Branded sales. Core operating profit declined 7% due to product mix and prior-year comparators, but the company expects a stronger H2...
Smith & Nephew plc

Smith & Nephew Plc delivers strong H1 with profit up 31%

Smith+Nephew reported 5.0% underlying revenue growth and a 30.6% rise in operating profit for H1 2025. EPS rose 36.6% to 33.5¢ and free cash flow surged to $244m. The company also announced a $500m share buyback for H2, supported by strong cash generation and margin expansion...
Aptamer Group

Aptamer Group reports 41% revenue growth and new licensing deals

Aptamer Group posted unaudited revenue of £1.20 million for the year ended 30 June 2025, up 41% from the previous year. The company secured two new royalty agreements and advanced multiple licensing discussions, supported by a strengthened cash position following a £1.83 million fundraise...
GSK plc

GSK raises 2025 guidance after strong Q2 performance

GSK reported Q2 2025 turnover of £8.0bn, up 6% CER, with strong growth in Specialty Medicines (+15%) and Vaccines (+9%). Core EPS rose 15% to 46.5p...
One Health Group

One Health Group a “buy” in This is Money Midas Share Tips

Analysts at Midas Share Tips described the company as well-managed and well-positioned to benefit from ongoing NHS reliance on external capacity...
GSK

GSK and Hengrui Pharma to develop up to 12 new medicine programmes

GSK plc has entered agreements with Hengrui Pharma to develop up to 12 innovative medicines, including an exclusive worldwide licence (ex‑China) for HRS‑9821, a potential best‑in‑class PDE3/4 inhibitor for COPD, for $500 million in upfront fees and up to $12 billion in milestone payments...
Physicians Capital

When buildings become health’s best asset

Investors are discovering that medical properties offer a unique blend of resilience and growth potential in unpredictable markets...
One Health Group

One Health Group PLC closely aligned with government 10-year Health Plan

AstraZeneca

AstraZeneca to invest $50bn in the US, new Virginia manufacturing site planned

AstraZeneca will invest $50bn in the United States by 2030, including a multi‑billion dollar drug substance facility in Virginia for its weight management and metabolic portfolio...

Oxford Nanopore delivers 25% revenue growth in H1 2025

Revenue rose to £105 million, up 28% constant currency, driven by PromethION growth of 59% and strong gains in Applied markets. Adjusted EBITDA loss narrowed, cash stood at £337 million and full‑year guidance remains on track...
Aptamer Group

Aptamer Group extends Unilever collaboration for deodorant Optimers

Aptamer Group has secured additional paid work from Unilever under their existing collaboration, advancing Optimers as deodorant actives with expanded stability testing ahead of on‑person trials...
GSK plc

GSK’s Arexvy FDA review accepted for adults 18-49 at increased risk

The US FDA has accepted GSK’s application to extend Arexvy to adults aged 18-49 at increased risk of severe RSV infection, supported by positive Phase IIIb data; a decision is expected in H1 2026...
AstraZeneca

AstraZeneca’s Baxdrostat meets Phase III endpoints in Hypertension trial

AstraZeneca reports that baxdrostat at 1mg and 2mg doses significantly reduced mean seated systolic blood pressure at 12 weeks versus placebo in patients with uncontrolled or treatment-resistant hypertension, meeting all primary and secondary endpoints, with a favourable safety profile...
Aptamer Group

Aptamer Group raises £2.0 million in share placing

Aptamer has raised £2.0 million (before expenses) by placing 666,666,666 new ordinary shares at 0.3 p each, representing 25.1 per cent of its enlarged issued share capital. The proceeds will accelerate commercialisation of the Optimer® platform, support in-house manufacturing, launch new biomarker services and develop AI-driven aptamer discovery...
Load More

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

Green News

View all Sustainable sectors, Plcs and news >>  

Search

Search

Latest interviews

Broker Talk

Funds

View all Funds, Market Insights and news >> 

FTSE 100 News

UK Broker Ratings

Health

Latest Interviews

FTSE 100 News

FTSE 250 News

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

BrokerTalk

FTSE 100

Funds

View all Funds, Market Insights and news >> 

Green News

View all Sustainable sectors, Plcs and news >>  

UK Broker Ratings

Follow us on Social Media:

Home X-twitter Linkedin Facebook Spotify Apple